Literature DB >> 3932449

Pulsatile luteinizing hormone patterns in the follicular phase of the menstrual cycle, polycystic ovarian disease (PCOD) and non-PCOD secondary amenorrhea.

C W Burger, T Korsen, H van Kessel, P A van Dop, F J Caron, J Schoemaker.   

Abstract

To characterize the oscillations of plasma LH in normally cycling and amenorrheic women, three groups of women were studied: I, normal women during the follicular phase of the cycle (n = 9); II, women with polycystic ovarian disease (PCOD; n = 11); and III, women with non-PCOD secondary amenorrhea (n = 12). Blood samples were obtained at 10-min intervals for 6 h on 2 separate days. A pulse was defined as an increase in LH at least 20% over the preceding lowest value (nadir). Since LHRH release immediately follows the nadir of the LH levels, the nadir interval (NI) was used for analysis. For analysis, the results from 1 day were selected at random from each subject, and from each day, the same number of NIs also were randomly selected. When two NIs from each patient were selected, the median NI was 75 min in group I, 45 min in group II, and 45 min in group III. When three or four NIs were chosen, the median NI was 60 min in group I, 50 min in group II, and 40 min in group III. The differences between the groups were statistically significant. When three NIs were selected, the mean of the corresponding LH amplitudes was 2.8 U/liter in group I, 6.0 U/liter in group II, and 1.5 U/liter in group III. The differences between these groups were statistically significant. Thus, the NI in PCOD patients was shorter than that during the follicular phase of the cycle, but this short NI is not unique for PCOD, since the NI in non-PCOD secondary amenorrhea patients was even smaller. The LH amplitude was higher in PCOD and lower in non-PCOD secondary amenorrhea compared to that during the follicular phase of the cycle. The decrease in NI in PCOD and/or non-PCOD secondary amenorrhea vs. the NI of the follicular phase could be explained by either a higher frequency of LHRH pulses from the hypothalamus or an increased sensitivity of the pituitary leading to a greater response of the pituitary to LHRH pulses.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3932449     DOI: 10.1210/jcem-61-6-1126

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Biomathematical modeling of pulsatile hormone secretion: a historical perspective.

Authors:  William S Evans; Leon S Farhy; Michael L Johnson
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

Review 2.  Hypersecretion of luteinizing hormone in the polycystic ovary syndrome and a novel hormone 'gonadotrophin surge attenuating factor'.

Authors:  A H Balen
Journal:  J R Soc Med       Date:  1995-06       Impact factor: 5.344

3.  Is changing hypothalamic activity important for control of ovulation?

Authors:  R N Clayton; J P Royston; J Chapman; M Wilson; M Obhrai; R S Sawers; S S Lynch
Journal:  Br Med J (Clin Res Ed)       Date:  1987-07-04

4.  Pulsatile secretion of luteinizing hormone in agonadal men before and during testosterone replacement therapy.

Authors:  A D Genazzani; G Forti; M Maggi; M Milloni; F Cianfanelli; V Guardabasso; V Toscano; M Serio; D Rodbard
Journal:  J Endocrinol Invest       Date:  1990-11       Impact factor: 4.256

Review 5.  Diagnostic criteria for polycystic ovarian syndrome.

Authors:  F J Broekmans; B C J M Fauser
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

6.  Luteinizing hormone pulsatility in patients with major ovarian hyperandrogenism.

Authors:  A Bachelot; K Laborde; J L Bresson; G Plu-Bureau; A Raynaud; X Bertagna; A Mogenet; M Mansour; V Lucas-Jouy; J-P Gayno; Y Reznik; J-M Kuhn; L Billaud; M-C Vacher-Lavenu; M Putterman; I Mowszowicz; P Touraine; F Kuttenn
Journal:  J Endocrinol Invest       Date:  2007-09       Impact factor: 4.256

Review 7.  Insights into hypothalamic-pituitary dysfunction in polycystic ovary syndrome.

Authors:  J E Hall; A E Taylor; F J Hayes; W F Crowley
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

8.  Metformin therapy in a hyperandrogenic anovulatory mutant murine model with polycystic ovarian syndrome characteristics improves oocyte maturity during superovulation.

Authors:  Mary E Sabatini; Lankai Guo; Maureen P Lynch; Joseph O Doyle; Hojoon Lee; Bo R Rueda; Aaron K Styer
Journal:  J Ovarian Res       Date:  2011-05-23       Impact factor: 4.234

9.  The mechanism of mTOR (mammalian target of rapamycin) in a mouse model of polycystic ovary syndrome (PCOS).

Authors:  Aylin Yaba; Necdet Demir
Journal:  J Ovarian Res       Date:  2012-11-27       Impact factor: 4.234

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.